₹439.65
−9.96%NSE close, 16 Nov 2026
−7.36%
Q-LINE BIOTECH is a small cap company, listed on NSE SME under the symbol QLINE. At ₹439.65 a share, the market values the whole company at ₹1,026 crore. NSE SME is the exchange's platform for small and medium companies, which report their results every half year.
In FY26, it reported sales of ₹342 crore and a net profit of ₹56 crore, an operating margin of 28.7%.
The market values the company at 19.0 times its profit over the last twelve months and 2.13 times its book value; its return on equity is 11.2% and its borrowings are 0.27 times its equity.
Promoters hold 67.51% of the shares. Foreign institutions hold 0.88%, and domestic institutions, mutual funds among them, 8.15%.
Listed on NSE SME, the platform for small and medium companies: its shares trade in large lots and often thinly, so the price can move sharply on a few trades, and companies file results every half year.
₹ crore. Consolidated figures.
| Line | 6M to Mar 2026 | 6M to Sep 2026 |
|---|---|---|
| Sales | 198 | 152 |
| Expenses | 136 | 113 |
| Operating profit | 62.1 | 39.6 |
| Operating margin | 31.4% | 26.0% |
| Other income | 3.0 | 4.1 |
| Interest | 11.1 | 9.8 |
| Depreciation | 6.7 | 7.9 |
| Profit before tax |
Submission of audio recording of Earnings Conference Call-13.11.2026
Link of Recording
SUBMISSION OF MONITORING AGENCY REPORT - FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2026.
PRESS RELEASE ON FINANCIAL RESULTS 30 SEPTEMBER 2026
| 25.9 |
| Tax | 11.9 | 6.3 |
|---|
| Net profit | 34.4 | 19.6 |
|---|
| EPS (₹) | 21.48 | 10.47 |
|---|
₹ crore, financial years to March.
| Line | FY26 |
|---|---|
| Sales | 342 |
| Expenses | 244 |
| Operating profit | 98.1 |
| Operating margin | 28.7% |
| Other income | 5.7 |
| Interest | 19.4 |
| Depreciation | 10.8 |
| Profit before tax | 72.6 |
| Tax | 16.8 |
| Net profit | 55.7 |
| EPS (₹) | 34.79 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY26 | 6M to Sep 2026 |
|---|---|---|
| From operations | 16.4 | −9.2 |
| From investing | −29.4 | −111 |
| From financing | 41.6 | 112 |
| Spent on fixed assets | −35.9 | −8.3 |
| Free cash flow | −19.5 | −17.5 |
Margins, returns, debt, tax and cash.
| Line | FY26 |
|---|---|
| Net margin | 16.3% |
| Operating margin | 28.7% |
| Return on equity | 22.6% |
| Return on capital employed | 19.5% |
| Return on assets | 10.0% |
| Debt to equity | 0.92 |
| Interest coverage | 4.70 |
| Debt to assets | 0.40 |
| Current ratio | 1.64 |
| Quick ratio | 1.19 |
| Cash ratio | 0.20 |
| Asset turnover | 0.61 |
| Fixed asset turnover | 2.88 |
| Inventory turnover | 1.40 |
| Receivables turnover | 2.70 |
| Gross margin | 60.8% |
| Cash from operations to profit | 29.0% |
| Effective tax rate | 23.2% |
FINANCIAL RESULTS - 30 SEPTEMBER, 2026
The financial results for the period ended September 30, 2026.
Board comments on fine levied by the Exchange
Schedule of meet
Clarification-'.that due to an inadvertent clerical error, the time in the subject line of the filing was mentioned as 3:00 P.M. instead of 4:15 P.M.We hereby clarify that the correct time of the Board Meeting is 4:15 P.M., as mentioned in the Board Meeting notice. The…
Voting results of Annual General Meeting held on September 30, 2026 and Scrutinizer Report
A copy Srutinizers report of Annual General Meeting held on September 30, 2026
Proceedings of Annual General Meeting held on September 30, 2026